J&J launches new iteration of nursing campaign (J&J)

'Where would the world be with­out nurs­es?' J&J re­fresh­es cam­paign hon­or­ing health work­ers

More than two and a half years in­to the pan­dem­ic, John­son & John­son wants to re­mind peo­ple that nurs­es are much more than just care­givers.

In the lat­est it­er­a­tion of its cam­paign, J&J hon­ors nurs­es as “in­no­va­tors, life­savers, and fierce pa­tient ad­vo­cates.” The pro­gram got a re­fresh from last year, in­clud­ing a new tagline, “Where Would the World Be With­out Nurs­es,” and videos that de­buted on so­cial me­dia on Thurs­day.

“Who would be there when no one else is?” a nar­ra­tor asks in J&J’s 30-sec­ond ad video that de­picts nurs­es scrub­bing up, per­form­ing CPR and com­fort­ing pa­tients.

J&J claims it has been a “proud cham­pi­on of nurs­es since 1897,” and launched a cam­paign in 2001 to dri­ve more peo­ple in­to the pro­fes­sion with the help of TV ad spots, grants, schol­ar­ships and more. There have been sev­er­al it­er­a­tions since, in­clud­ing last year’s “Nurs­es Rise to the Chal­lenge Every Day” cam­paign.

Lyn­da Ben­ton

“Last year, we were just re­al­ly fo­cused on try­ing to en­gage and sup­port and re­mind nurs­es that we saw their val­ue,” said Lyn­da Ben­ton, se­nior di­rec­tor of glob­al com­mu­ni­ty im­pact strate­gic ini­tia­tives for J&J Nurs­ing. “Now we want to open the lens and get a broad­er health­care com­mu­ni­ty to un­der­stand what nurs­es bring to health­care.”

The ads are meant to ad­dress “alarm­ing lev­els of burnout” in the nurs­ing field, J&J said. A re­port pub­lished last year by the Amer­i­can As­so­ci­a­tion of Crit­i­cal-Care Nurs­es found that 66% of sur­veyed acute and crit­i­cal care nurs­es had con­sid­ered leav­ing their jobs be­cause of the pan­dem­ic. The Amer­i­can Nurs­es As­so­ci­a­tion al­so urged the HHS sec­re­tary in a let­ter last year to de­clare the nurse staffing short­age a na­tion­al cri­sis.

In 2022, health­care em­ploy­ment has in­creased at a sig­nif­i­cant­ly high­er month­ly rate than last year’s, ac­cord­ing to the Bu­reau of La­bor Sta­tis­tics. But there’s more to be done, J&J em­pha­sized.

“When you think about ear­ly 2020, the world was ba­si­cal­ly cheer­ing on the nurs­ing work­force and thank­ing them for all they were do­ing to care for pa­tients,” Ben­ton said. “As the pan­dem­ic wore on, and the vac­cines start­ed com­ing out … in some cas­es life went back to nor­mal and [peo­ple] kind of for­got about the nurs­es who were still work­ing in­side the walls of the hos­pi­tal and sav­ing lives on a day-to-day ba­sis.”

The lat­est cam­paign is com­ple­ment­ed by videos spot­light­ing the next gen­er­a­tion of nurs­es, and a ‘To­day” show seg­ment called “He­roes Among Us.”

“If we don’t ad­dress this, this is a health­care cri­sis for every­body,” Ben­ton said. “It’s just so im­por­tant that peo­ple will re­al­ly wake up and un­der­stand what’s hap­pen­ing to­day with­in the nurs­ing pro­fes­sion.”

Am­gen lays off about 300 work­ers, cit­ing 'in­dus­try head­wind­s'

Amgen has laid off about 300 employees, a company spokesperson confirmed to Endpoints News via email Sunday night.

Employees posted to LinkedIn in recent days about layoffs hitting Amgen last week. The Thousand Oaks, CA-based biopharma, which employs about 24,000 people, said the reduction “mainly” impacted US-based workers on its commercial team.

Drug developers of all sizes, including small upstarts and pharma giants, have let employees go in recent months as the biopharma market drags through a quarters-long winter doldrum.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Bradway, Amgen CEO (Stephen Lam/Reuters)

Am­gen launch­es the first US Hu­mi­ra biosim­i­lar at two dif­fer­ent list prices

The bizarre dynamics of the US prescription drug market were on full display once again this morning as Amgen announced that it would launch the first US biosimilar for Humira, the best-selling drug of all time, at two completely different list prices.

One price for Amgen’s Amjevita (adalimumab-atto) will be 55% below the current Humira list price, which is about $84,000 per year, and another at a list price 5% below the current Humira list price, but presumably (pharma companies don’t disclose rebates) with high rebates to attract PBMs and payers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Credit: Shutterstock

New York City in­vests $20M in­to biotech 'in­no­va­tion space' at the Brook­lyn Navy Yard

New York City is investing $20 million in biotech this year in the form of a 50,000-square-foot “innovation space” at the Brooklyn Navy Yard, complete with offices, research laboratories and events and programming space to grow biotech startups and companies.

Mayor Eric Adams said during his State of The City Address last Thursday that there will be an “emphasis” on making more opportunities for women and people of color to further diversify the industry. The City first reported the news.

Dirk Thye, Quince Therapeutics CEO

Af­ter piv­ot­ing from Alzheimer's to bone con­di­tions, biotech piv­ots again — and halves its head­count

When troubled public biotech Cortexyme bought a private startup named Novosteo and handed the keys to its executive team, the company — which changed its name to Quince Therapeutics — said it would shift its focus from an unorthodox Alzheimer’s approach to Novosteo’s bone-targeting drug platform.

Less than a year later, Quince is pivoting again.

The biotech has decided to out-license its bone-targeting drug platform and its lead drug, NOV004, and instead look for clinical-stage programs to in-license or acquire, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Boehringer In­gel­heim touts pre­ven­tion re­sults in rarest form of pso­ri­a­sis

Boehringer Ingelheim uncorked some positive results suggesting that Spevigo can help prevent flare-ups in patients with a severe form of psoriasis, months after the drug was approved to treat existing flares.

Spevigo, an IL-36R antibody also known as spesolimab, met its primary and a key secondary endpoint in the Phase IIb EFFISAYIL 2 trial in patients with generalized pustular psoriasis (GPP), Boehringer announced on Monday. While the company is keeping the hard numbers under wraps until later this year, it said in a news release that it anticipates sharing the results with regulators.

As­traZeneca, No­vo Nordisk and Sanofi score 340B-re­lat­ed ap­peals court win over HHS

AstraZeneca, Novo Nordisk, and Sanofi won an appeals court win on Monday, as the US Court of Appeals for the Third Circuit found that the companies cannot be forced to provide 340B-discounted drugs purchased by hospitals from an unlimited number of community and specialty pharmacies.

“Legal duties do not spring from silence,” the decision says as the court makes clear that the federal government’s interpretation of the “supposed requirement” that the 340B program compels drugmakers to supply their discounted drugs to an unlimited number of contract pharmacies is not correct, noting:

Ap­peals court toss­es J&J's con­tro­ver­sial 'Texas two-step' bank­rupt­cy case

A US appeals court has ruled against Johnson & Johnson’s use of bankruptcy to deal with mounting talc lawsuits, deciding that doing so would “create a legal blind spot.”

The Third Circuit Court of Appeals reversed a previous bankruptcy court decision on Monday, calling for the dismissal of a Chapter 11 filing by J&J’s subsidiary LTL Management.

Faced with more than 38,000 lawsuits alleging its talc-based products caused cancer, J&J spun its talc liabilities into a separate company called LTL Management back in October 2021 and filed for bankruptcy, a controversial move colloquially referred to as a “Texas two-step” bankruptcy. Claimants argued that the strategy is a misuse of the US bankruptcy code — and on Monday, a panel of judges agreed.

A new Genentech 'MS Visibility' campaign video features Black women living with or connected to MS talking about their experiences. (Genentech)

Roche’s Genen­tech de­buts next it­er­a­tion of MS cam­paign, high­lights ex­pe­ri­ences in Black com­mu­ni­ty

Roche’s Genentech is tackling diversity in multiple sclerosis again, this time with a focus on the Black community. Its “MS Visibility” effort, debuted in 2021, is now adding to the awareness campaign with new work that includes a set of videos featuring discussions among Black women and healthcare professionals.

“They’re incredibly inspiring Black women living with or connected to MS and they’re having just honest conversation about their experience and the unique barriers that their community faces,” said Jennifer Kim, head of neuroimmunology at Genentech marketing.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Richard Gonzalez, AbbVie CEO (Chris Kleponis/picture-alliance/dpa/AP Images)

Up­dat­ed: $100B+ in sav­ings? Why the in­com­ing Hu­mi­ra biosim­i­lars will take time to catch on

The 20-year reign of AbbVie’s best-selling biologic of all time — the autoimmune disease biologic Humira (adalimumab) that has brought in upwards of $200 billion during its monopoly — is coming to an end tomorrow with the launch of Amgen’s biosimilar Amjevita.

The launch comes more than four years after Europe saw the exact same competition, leading to steep discounts in price, higher uptake, and big cost savings across the board.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.